CoChat

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

Objective Tumour-infiltrating lymphocyte (TIL) response and deficient DNA mismatch repair (dMMR) are determinants of prognosis in colorectal cancer. Although highly correlated, evidence suggests that these are independent predictors of outcome. However, the prognostic significance of combined TIL/MMR classification and how this compares to the major genomic and transcriptomic subtypes remain unclear. Design A prospective cohort of 1265 patients with stage II/III cancer was examined for TIL/MMR status and BRAF / KRAS mutations. Consensus molecular subtype (CMS) status was determined for 142 cases. Associations with 5-year disease-free survival (DFS) were evaluated and validated in an independent cohort of 602 patients. Results Tumours were categorised into four subtypes based on TIL and MMR status: TIL-low/proficient-MMR (pMMR) (61.3% of cases), TIL-high/pMMR (14.8%), TIL-low/dMMR (8.6%) and TIL-high/dMMR (15.2%). Compared with TIL-high/dMMR tumours with the most favourable prognosis, both TIL-low/dMMR (HR=3.53; 95% CI=1.88 to 6.64; P multivariate <0.001) and TIL-low/pMMR tumours (HR=2.67; 95% CI=1.47 to 4.84; P multivariate =0.001) showed poor DFS. Outcomes of patients with TIL-low/dMMR and TIL-low/pMMR tumours were similar. TIL-high/pMMR tumours showed intermediate survival rates. These findings were validated in an independent cohort. TIL/MMR status was a more significant predictor of prognosis than National Comprehensive Cancer Network high-risk features and was a superior predictor of prognosis compared with genomic (dMMR, pMMR/ BRAF wt / KRAS wt , pMMR/ BRAF mut / KRAS wt , pMMR/ BRAF wt / KRAS mut ) and transcriptomic (CMS 1-4) subtypes. Conclusion TIL/MMR classification identified subtypes of stage II/III colorectal cancer associated with different outcomes. Although dMMR status is generally considered a marker of good prognosis, we found this to be dependent on the presence of TILs. Prognostication based on TIL/MMR subtypes was superior compared with histopathological, genomic and transcriptomic subtypes.

Overview

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2017-315664

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 84

Metadata

Authors
Williams, D. S., Mouradov, D., Jorissen, R. N., Newman, M. R., Amini, E., Nickless, D. K., Teague, J. A., Fang, C. G., Palmieri, M., Parsons, M. J., Sakthianandeswaren, A., Li, S., Ward, R. L., Hawkins, N. J., Faragher, I., Jones, I. T., Gibbs, P., & Sieber, O. M.
Affiliations
  • Austin Health (AU)
  • The University of Melbourne (AU)
  • Sonic Healthcare (Germany) (DE)
  • Northern Hospital (AU)
  • Olivia Newton-John Cancer Research Institute (AU)
  • Walter and Eliza Hall Institute of Medical Research (AU)
  • The University of Queensland (AU)
  • Footscray Hospital (AU)
  • The Royal Melbourne Hospital (AU)
Corresponding author
Sieber, Oliver M
Venue
Gut
Publisher
BMJ
Published
2018-01-30
Volume
68
Issue
3
Pages
465-474
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2786855717
Cited by
79
References
49
Citations by year
2026: 5 · 2025: 12 · 2024: 8 · 2023: 7 · 2022: 13 · 2021: 10 · 2020: 11 · 2019: 10 · 2018: 3
FWCI
6.47
Type
journal article
Language
en
Open access
closed
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Cancer Therapeutics CRC
  • Australian Government
  • Cancer Council Victoria
  • National Health and Medical Research Council
  • Cancer Australia
  • Austin Medical Research
  • State Government of Victoria
  • University of Melbourne
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
tumor-infiltrating lymphocytes, colorectal cancer, stage II and III colorectal cancer, tumor subtypes, disease-free survival, prognosis, consensus molecular subtypes, BRAF mutation, KRAS mutation, antitumor immunity, prognostic factors, microsatellite instability, mismatch repair deficiency, tumor suppressor
MeSH terms
Adenocarcinoma, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies, Colorectal Neoplasms, Reproducibility of Results, Lymphocytes, Tumor-Infiltrating, Lymphocyte Count, Genomics, Kaplan-Meier Estimate, DNA Mismatch Repair, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.